Alector, INC Form 4 insider transactions

Alector, Inc. CEO Arnon Rosenthal sold 51,562 shares of common stock to cover tax obligations related to restricted stock unit vesting.

Alector Director Paula Hammond sold 14,000 shares of common stock for $2.357 per share, as part of a pre-arranged 10b5-1 trading plan.

Alector, Inc.'s Principal Financial Officer, Neil Lindsay Berkley, was granted 18,000 employee stock options with an exercise price of $1.42 per share.

Alector, Inc.'s President and Head of R&D, Sara Kenkare-Mitra, has acquired 54,725 restricted stock units and 18,250 employee stock options, aligning executive incentives with future company performance.

Alector, Inc.'s Chief Executive Officer, Arnon Rosenthal, has acquired 137,125 restricted stock units and 45,700 employee stock options, significantly increasing his beneficial ownership in the company.

Alector, Inc. Director Kristine Yaffe reported the sale of 1,000 shares of common stock for $1.44 per share, executed under a Rule 10b5-1 trading plan.

Alector, Inc. Director Paula Hammond was granted 28,700 restricted stock units and options to purchase 9,450 shares of common stock on June 11, 2025, as part of her compensation.

Alector, Inc. Director Kristine Yaffe reported the acquisition of 28,700 restricted stock units and 9,450 stock options on June 11, 2025, increasing her beneficial ownership in the company.

Alector, Inc. Director Elizabeth A. Garofalo was granted 28,700 restricted stock units and options to purchase 9,450 shares of common stock, aligning her interests with shareholders.

Alector, Inc. Director Richard H. Scheller was granted 28,700 restricted stock units and 9,450 stock options, aligning his interests with shareholders.

Alector, Inc. Director Louis J. Lavigne Jr. was granted 28,700 restricted stock units and options to purchase 9,450 shares of common stock, signaling continued alignment with shareholder interests.

Alector, Inc. Director Errol B. Desouza reported the acquisition of 28,700 restricted stock units and 9,450 stock options on June 11, 2025, as part of his compensation.

Alector, Inc. Director Mark Altmeyer was granted 28,700 restricted stock units and options to purchase 9,450 shares of common stock, aligning his interests with shareholders.

Alector, Inc.'s Chief Financial Officer, Marc Grasso, sold 16,488 shares of common stock to satisfy tax obligations related to the vesting of restricted stock units.

Alector, Inc.'s President and Head of R&D, Sara Kenkare-Mitra, sold 23,890 shares of common stock on June 2, 2025, at a weighted average price of $1.3384 to satisfy tax obligations related to restricted stock unit vesting.

Alector, Inc. CEO Arnon Rosenthal reported the sale of 52,087 shares of common stock on June 2, 2025, to satisfy tax obligations related to restricted stock unit vesting.

Director Richard H. Scheller reports acquiring 15,833 shares of Alector, Inc. stock through restricted stock units and disposing of 66,666 shares.

Alector's CEO, Arnon Rosenthal, sold shares of common stock on March 3, 2025, to cover tax obligations related to vesting restricted stock units.

Gary Romano, Chief Medical Officer of Alector, Inc., sold shares of common stock on March 3, 2025, to cover tax obligations related to vesting restricted stock units.

Sara Kenkare-Mitra, President and Head of R&D at Alector, Inc., sold shares of common stock to satisfy tax obligations related to vesting restricted stock units.

Alector's Chief Financial Officer, Marc Grasso, sold shares of common stock on March 3, 2025, to satisfy tax obligations related to vesting restricted stock units.

Alector's Chief Financial Officer, Marc Grasso, sold 16,489 shares of common stock to cover tax obligations related to vesting restricted stock units.

Alector's CEO, Arnon Rosenthal, sold 52,172 shares of common stock to cover tax obligations related to vested restricted stock units.

Alector Inc.'s President and Head of R&D, Sara Kenkare-Mitra, sold 26,500 shares of common stock to cover tax obligations related to vesting restricted stock units.

Alector's Chief Medical Officer, Gary Romano, sold 14,892 shares of common stock to cover tax obligations related to vesting restricted stock units.

Director Richard H. Scheller reports acquisition and disposal of Alector, Inc. stock, including restricted stock units vesting quarterly starting September 1, 2024.

Alector's Chief Financial Officer, Marc Grasso, recently acquired 216,400 shares of common stock through restricted stock units.

Sara Kenkare-Mitra, President and Head of R&D at Alector, Inc., reports acquiring 300,000 shares of common stock through restricted stock units.

Alector's CEO, Arnon Rosenthal, acquired 610,500 shares of common stock through restricted stock units vesting quarterly, while also reporting indirect ownership through family trusts.

A Form 4 filing reveals that Alector's Chief Medical Officer, Gary Romano, acquired 184,380 restricted stock units (RSUs) on October 1, 2024.